Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics announced that its CEO, David Stamler, will present a corporate update at the Biotech Showcase. This presentation highlights the company’s progress, particularly the positive data from its ATH434 trials for Multiple System Atrophy, potentially strengthening its position in the neurodegenerative disease treatment market.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials and is based in Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: 40.0%
Average Trading Volume: 13,444,263
Technical Sentiment Signal: Sell
Current Market Cap: A$128.9M
Learn more about ATH stock on TipRanks’ Stock Analysis page.